- Adherence
- Children
- Clinical reviews
- Drug supply
- Guidelines
- Hepatitis and HIV coinfection
- HIV Testing
- Infant feeding
- Laboratory monitoring
- Malaria & HIV
- Neurological problems, including HIV dementia
- Nutrition
- Palliative care
- Prevention
- Prevention of mother-to child transmission
- Scaling up treatment and models of service delivery
- Side-effects
- South Africa
- Starting treatment
- First-line antiretroviral therapy: not as simple as we'd like it to be - 19/06/08
- How to deliver good adherence support: lessons from round the world - 10/9/2007
- WHO to monitor ARV side-effects worldwide - 11/9/2007
- First-line treatment choices proving challenging for African ART programmes - 11/9/2007
- A follow-up on follow-up: shifting to a community-based response to improve retention in care - 31/8/2007
- Patient retention challenges and the need for more active follow-up - 22/3/2007
- Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
- Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part One - 27/10/2005
- Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part Two - 27/10/2005
- Immune reconstitution inflammatory syndrome (IRIS) in the developing world - 27/10/2005
- Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
- Fixed-dose ARV combinations: choices and challenges - 27/10/2005
- Monitoring ARV treatment - 27/10/2005
- Combining ARVs with treatment for tuberculosis - 27/10/2005
- Nevirapine-based fixed-dose combination ARVs - 27/10/2005
- Co-trimoxazole prophylaxis - 27/10/2005
- Stigma
- Task shifting
- Treatment failure
- Tuberculosis
- Viral load testing
Starting treatment
First-line antiretroviral therapy: not as simple as we'd like it to be - 19/06/08
How to deliver good adherence support: lessons from round the world - 10/9/2007
WHO to monitor ARV side-effects worldwide - 11/9/2007
First-line treatment choices proving challenging for African ART programmes - 11/9/2007
A follow-up on follow-up: shifting to a community-based response to improve retention in care - 31/8/2007
Patient retention challenges and the need for more active follow-up - 22/3/2007
Lowering the threshold - Is there a case for re-evaluating eligibility criteria for ART? - 1/11/2006
Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part One - 27/10/2005
Treatment equity in practice: how scarce resources for treatment are being used, and the ethical dilemmas that need to be debated - Part Two - 27/10/2005
Immune reconstitution inflammatory syndrome (IRIS) in the developing world - 27/10/2005
Symptoms versus laboratory monitoring as criteria for starting treatment - 27/10/2005
Fixed-dose ARV combinations: choices and challenges - 27/10/2005
Monitoring ARV treatment - 27/10/2005
Combining ARVs with treatment for tuberculosis - 27/10/2005
Nevirapine-based fixed-dose combination ARVs - 27/10/2005
Co-trimoxazole prophylaxis - 27/10/2005
About HATIP
A regular electronic newsletter for health care workers and community-based organisations on HIV treatment in resource-limited settings.
Its publication is supported by the UK government's Department for International Development (DfID), the Diana, Princess of Wales Memorial Fund and the Stop TB Department of the World Health Organization.
Other supporters include Positive Action GlaxoSmithKline (founding sponsor); Abbott Fund; Abbott Molecular; Cavidi; Elton John AIDS Foundation; Merck & Co., Inc.; Pfizer Ltd; F Hoffmann La Roche; Schering Plough; and Tibotec, a division of Janssen Cilag.
latest aidsmap news
- High rate of death amongst patients with HIV diagnosed late
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
- Raltegravir may have role in PEP if exposure involves drug-resistant HIV
- Excellent outcomes from five years of antiretroviral use in Botswana
- Study explores verbal and non-verbal communication in unprotected sex between men
- IL-2 provides quick ‘AIDS rescue’, but effect does not always last
- Once-a-day etravirine should work as first-line treatment
- Second-line combinations fail twice as often as first-line ones in the first year
- If you can't switch, better to stay on failing treatment than stop it, studies show
- Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’